January 14th, 2016 – The Chemical Diversity Research Institute of ChemDiv, Inc (ChemDiv), San Diego, CA – based global research organization and Abbott’s branded generics pharmaceutical business have extended their existing collaboration to develop and register a pipeline of new branded generic pharmaceutical products for high growth emerging markets.
The expansion is the result of the successful existing partnership between Abbott and ChemDiv for the discovery and development of new pharmaceutical products and treatment alternatives in multiple therapeutic areas.
As part of this renewed collaboration, ChemDiv is developing product formulations and undertakes pre-clinical and clinical studies on a number of products. It also enables product registration and technology transfer to the manufacturing of new products that Abbott will market in Russia, CIS, and other high growth emerging markets in Asia, Africa and Latin America.
Nikolay Savchuk, Chairman of the Board for ChemDiv Research Institute said: “We are extremely pleased that our strategic partnership with Abbott has progressed so well. Through our global development expertise and strong regional regulatory expertise, we support the development of a product pipeline that will help improve the lives of people and improve their health outcomes.”
About ChemDiv and ChemDiv Research Institute:
ChemDiv a global research organization based in San Diego, California. The ChemDiv Research Institute R&D facilities are located at Torrey Pines Center in San Diego, while the ChemRar High Tech Center and Skolkovo Life Science Cluster are located in Moscow. For 25 years ChemDiv accelerates and enables pharma and biotech R&D programs from research concepts to registered drugs, targeting broad spectrum of unmet medical needs.
Contacts for media: